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Background and Purpose  Detecting antibodies against muscle-specific tyrosine kinase 
(MuSK Abs) is essential for diagnosing myasthenia gravis (MG). We applied an in-house cell-
based assay (CBA) to detect MuSK Abs.
Methods  A stable cell line was generated using a lentiviral vector, which allowed the expres-
sion of MuSK tagged with green fluorescent protein in human embryonic kidney 293 (HEK293) 
cells. Serum and anti-human IgG antibody conjugated with red fluorescence were added. The 
presence of MuSK Abs was determined based on the fluorescence intensity and their colocal-
ization in fluorescence microscopy. Totals of 218 serum samples collected from 177 patients 
with MG, 31 with other neuromuscular diseases, and 10 healthy controls were analyzed. The 
CBA results were compared with those of a radioimmunoprecipitation assay (RIPA) and an 
enzyme-linked immunosorbent assay (ELISA).
Results  The MuSK-HEK293 cell line stably expressed MuSK protein. The CBA detected 
MuSK Abs in 34 (19.2%) of 177 samples obtained from patients with MG and in none of the 
participants having other neuromuscular diseases or in the healthy controls. The clinical char-
acteristics of the patients with MuSK MG determined based on the CBA were strongly corre-
lated with known clinical features of MuSK MG. There was an almost perfect agreement be-
tween the results of the CBA and those of the RIPA (Cohen’s kappa=0.880, p<0.001) and ELISA 
(Cohen’s kappa=0.982, p<0.001).
Conclusions  The results of the in-house CBA showed excellent agreement with both the RIPA 
and ELISA. Our in-house CBA can be considered a reliable method for detecting MuSK Abs.
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Evaluating an In-House Cell-Based Assay for Detecting 
Antibodies Against Muscle-Specific Tyrosine Kinase  
in Myasthenia Gravis
INTRODUCTION
Muscle-specific tyrosine kinase (MuSK) is a transmembrane protein required for the dif-
ferentiation and maintenance of the neuromuscular junction that plays an important role 
in the clustering of acetylcholine receptors (AChRs). Reportedly 40–70% of generalized my-
asthenia gravis (MG) patients without AChR antibodies (AChR Abs) have antibodies against 
MuSK (MuSK Abs). Diagnosing MuSK-Ab-positive MG (MuSK MG) is important since 
patients with MuSK Abs often exhibit adverse responses to pyridostigmine, are likely to 
benefit from plasma exchange, and are considered to be less responsive to thymectomy.1 
Although patients with MuSK MG display some characteristic clinical features, including 
predominant bulbar involvement and muscle atrophy,2,3 a substantial proportion of pa-
tients with AChR-Ab-positive MG and double-seronegative MG (AChR-Ab negative and 
MuSK-Ab negative) also demonstrate bulbar weakness.4,5 In addition, it can be difficult to 
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discriminate MuSK MG from AChR-Ab-positive MG based 
solely on clinical information.6,7 Therefore, detecting MuSK 
Abs is crucial for the proper diagnosis and management of 
MuSK MG. 
The radioimmunoprecipitation assay (RIPA) is a widely 
used method for detecting autoantibodies in patients with 
MG. However, the radiation hazard associated with this as-
say means that it can only be performed in a small number 
of laboratories with trained personnel and an appropriate li-
cense. Antibodies can also be detected using cell-based assays 
(CBAs) that utilize living cells, thus mimicking the physio-
logical microenvironment. CBAs have recently been shown 
to be more sensitive in detecting autoantibodies in MG than 
is the conventional RIPA. Up to 66% of patients with MG who 
were previously believed to be negative for AChR Abs were 
found to have antibodies against clustered AChR through 
the application of a CBA.8,9 Other studies have similarly dem-
onstrated the presence of MuSK Abs through CBAs that were 
previously not detected in an RIPA.10,11 In short, a CBA pro-
vides a higher sensitivity for the diagnosis of MG without 
the radiation hazard associated with an RIPA. Therefore, an 
increasing number of patients who would previously have 
been regarded as seronegative are now being correctly diag-
nosed by using CBAs.
In the present study, we developed an in-house CBA and 
used it to evaluate the serostatus of MuSK Abs in patients with 
MG. We also tested MuSK Abs in patients with other neuro-
muscular diseases and in healthy volunteers as negative con-
trols. We evaluated the reliability of the in-house CBA by com-
paring the results with those from a commercially available 
RIPA and enzyme-linked immunosorbent assay (ELISA). 
METHODS
Patients
We tested 218 serum samples collected from October 2016 
to September 2019: 177 were obtained from patients with 
MG, 8 from patients with Lambert-Eaton myasthenic syn-
drome (LEMS), 17 from patients with chronic inflammato-
ry demyelinating polyradiculoneuropathy (CIDP), 3 from 
patients with amyotrophic lateral sclerosis, 3 from patients 
with idiopathic inflammatory myopathy, and 10 from healthy 
controls. MG was diagnosed based on clinical features, dec-
rement responses in low-frequency repetitive nerve stimula-
tion, improvement of symptoms after the intramuscular in-
jection of neostigmine, and serum concentrations of AChR 
Abs and/or MuSK Abs. LEMS, CIDP, amyotrophic lateral 
sclerosis, and idiopathic inflammatory myopathy were diag-
nosed based on commonly used diagnostic criteria for each 
disease.12-15 
The antibody profiles of the 177 patients with MG were 
categorized into 5 groups based on the results of commer-
cially available AChR Ab and MuSK Ab assays, which were 
previously applied while diagnosing MG: 1) AChR-Ab pos-
itive and MuSK Abs not tested, 2) AChR-Ab negative and 
MuSK-Ab positive, 3) AChR-Ab negative and MuSK-Ab 
borderline, 4) double seronegative (AChR-Ab negative and 
MuSK-Ab negative), and 5) AChR-Ab negative and MuSK 
Abs not tested. MuSK Abs were not tested in those patients 
who refused the test while diagnosing MG. All patients pro-
vided written informed consent, and the Yonsei University 
Severance Hospital Institutional Review Board approved this 
study (No. 4-2016-0601).
Data collection
Basic demographic and clinical data of the patients, includ-
ing sex, age at onset, age at diagnosis, initial symptoms, pres-
ence of MG crisis, Myasthenia Gravis Foundation of America 
(MGFA) clinical classification, and the state of immunosup-
pressive treatment, were recorded by reviewing medical re-
cords. The MGFA clinical classification represents the sever-
ity of MG and ranges from class I (ocular muscle weakness 
only) to class V (intubation required).16 The results for AChR 
Ab and MuSK Ab titers performed during the course of di-
agnoses were also recorded. AChR Abs were analyzed using 
a commercially available RIPA (anti-AChR-binding anti-
body, Seoul Clinical Laboratories, Seoul, Korea), with a re-
sult of AChR Abs >0.5 nmol/L considered positive. An anti-
MuSK Ab assay was applied using a commercially available 
RIPA (anti-MuSK Ab, Athena Diagnostics, Worcester, MA, 
USA). Before June 2015, the results were reported as nega-
tive (<10 titer units), borderline (≥10 titer units and <20 titer 
units), or positive (≥20 titer units). After June 2015, the re-
sults were provided in numerical values, and a result of >0.02 
nmol/L was considered positive. 
Development of a stable cell line expressing MuSK
MuSK cDNA was amplified and cloned into the Sgf I and 
Mlu I sites of the pLenti-C-mGFP-P2A-Puro cloning vector 
(OriGene, Rockville, MD, USA). The cloned MuSK plasmids 
or empty vector plasmids were transfected with lentiviral 
packaging plasmid (OriGene) into human embryonic kid-
ney 293 (HEK293) cells (Korean Cell Line Bank, Seoul, Ko-
rea) using Lipofectamine 2000 (Invitrogen, Carlsbad, CA, 
USA) on cell culture dishes. The transfected cells were cul-
tured in a cell culture incubator at 37°C and 5% CO2, with 
the culture medium changed after 12 h of incubation. After 
two days of incubation, the first batch of lentiviral superna-
tant was harvested, and 10 mL of fresh cell culture medium 
was added to the cell culture. The day after the first harvest, 
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the second batch of viral supernatant was collected. The len-
tiviral supernatant was filtered through a 0.45 μm filter. To 
generate a stable HEK293 cell line expressing MuSK, the 
MuSK cDNA containing lentiviral particles was added to the 
target HEK293 cells, which were cultured in the medium 
containing 1 μg/mL puromycin dihydrochloride (Life Tech-
nologies, Carlsbad, CA, USA). The puromycin-resistant cells 
were isolated after 1 week and then cloned by serial dilution. 
The individual stable transduced clones were screened for 
green fluorescent protein (GFP) expression using fluores-
cence microscopy. The expression of MuSK mRNA and pro-
tein was confirmed using the reverse-transcription polymerase 
chain reaction (RT-PCR) with three different primer pairs 
and Western blotting with an anti-MuSK antibody (Santa 
Cruz Biotechnology, Santa Cruz, CA, USA), respectively. The 
following primer pairs were used for the RT-PCR: MuSK1, 
forward 5’-CCTTCAGCGGAACTGAGAAA-3’ and reverse 
5’-GAGTCCTGGCTTGGTGATAAA-3’; MuSK2, forward 
5’-AGTGCCTACTCCTATTCCCATTT-3’ and reverse 
5’-CTCTCCGATGTCTCTCACATATTC-3’; MuSK3, for-
ward 5’-GGCAGAATTTGACAACCCTAAC -3’ and reverse 
5’-GCCATCTCGCACGTAGTAAA-3’; and GAPDH, for-
ward 5’-ATGGCACCGTCAAGGCTGAGA-3’ and reverse 
5’-GGCATGGACTGTGGTCATGAG-3’. Untransduced 
HEK293 cells and HEK293 cells transduced with empty vec-
tors were used as negative controls. The cells were progres-
sively cryofrozen to -80°C in solution comprising 90% fetal 
bovine serum (FBS; Gibco, Carlsbad, CA, USA) and 10% di-
methyl sulfoxide (Sigma Aldrich, St. Louis, MO, USA), and 
then stored in liquid nitrogen on the following day.
Immunofluorescence staining and analysis
After thawing, the stably transduced HEK293 cells express-
ing MuSK tagged with GFP were seeded on a coverslip (SPL 
Life Science, Pocheon, Korea) coated with poly-L-lysine (Sig-
ma Aldrich) and placed in wells of 24-well cell culture plates. 
The cells were grown in DMEM (GE Healthcare, Chicago, 
IL, USA) supplemented with 10% FBS (GE Healthcare), 100 
units/mL penicillin (Invitrogen, Carlsbad, CA, USA), and 
100 μg/mL streptomycin (Invitrogen) at 37°C and 5% CO2 
to 70–80% confluence. The culture medium was gently re-
moved and the cells were rinsed three times with DMEM 
containing 20 mM HEPES. The cells were incubated with 
rabbit polyclonal anti-MuSK antibody (Invitrogen; 50 μg/mL 
final concentration) or sera from patients or controls (dilut-
ed 1:20) in Dulbecco’s Modified Eagle’s medium (DMEM) 
containing 1% bovine serum albumin and 20 mM HEPES, 
for 1 h at room temperature. The cells were washed three 
times with DMEM containing 20 mM HEPES and fixed with 
4% paraformaldehyde in phosphate-buffered saline (PBS) 
for 15 min at room temperature. After washing with PBS, the 
cells were incubated with goat ant-rabbit IgG conjugated with 
Alexa Fluor 594 (Abcam, Cambridge, UK; dilution 1:750, 
2.67 μg/mL final concentration) to detect rabbit polyclonal 
MuSK Abs, or with goat anti-human IgG (H+L) conjugated 
with Alexa Fluor 594 (Invitrogen; dilution 1:750, 2.67 μg/mL 
final concentration) to detect MuSK Abs in patients’ serum 
for 45 min at room temperature in the dark. The goat anti-
human IgG (H+L) used in the present study binds to both 
heavy and light chains of human immunoglobulin. After 
washing three times with PBS, the coverslips were gently re-
moved from the 24-well plates and placed on microscope 
slides with VECTASHIELD antifade mounting medium con-
taining 4’,6-diamidino-2-phenylindole (DAPI; Vector Lab-
oratories, Burlingame, CA, USA). The slides were stored in 
darkness at 4°C before being observed using fluorescence 
microscopy.
Immunofluorescence staining was evaluated using a fluo-
rescence microscope (Zeiss, Oberkochen, Germany). The in-
tensity of fluorescence on the cell membrane and the colocal-
ization of the GFP-labeled MuSK (green fluorescence) with 
Alexa Fluor 594-labeled antibody (red fluorescence) was as-
sessed using a previously described visual scoring system: 0 
for no labeling of the transduced cells, 0.5 for very weak la-
beling of a few cells with no definite colocalization, 1 for weak 
labeling of some cells with colocalization, 2 for labeling of 20–
50% of cells with accurate colocalization, 3 for labeling of 
50–80% of cells with perfect colocalization, and 4 for label-
ing of all transduced cells showing perfect colocalization.9,17 
A score of 1 or more was considered a positive result. The re-
sults were interpreted using consensus by two independent 
investigators (M.K. and S.W.K.) who were blinded to the clin-
ical data.
Enzyme-linked immunosorbent assay
All 218 serum samples were evaluated with MuSK Abs ELI-
SA (IBL International, Männedorf, Germany) according to 
the manufacturer’s instructions. Both positive and negative 
control serum samples were used to monitor the performance 
of the ELISA. The concentration of the MuSK Abs was calcu-
lated by referring to standard curves. All assays were performed 
in duplicate, with the final concentration calculated by aver-
aging the results. The result was considered positive if the 
concentration of the MuSK Abs was >0.4 U/mL. 
Statistical analysis
The data are expressed as percentages for categorical vari-
ables and mean±standard deviation values for continuous 
variables, depending on the assumption of normality. Over-
all comparisons between three groups were conducted by a 
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chi-square test for categorical variables and ANOVA for con-
tinuous variables. Cohen’s kappa coefficient was used to an-
alyze the agreement in determining a positive result for MuSK 
Abs between the CBA, RIPA, and ELISA. The CBA and ELI-
SA were applied during this study using the same samples, 
whereas the RIPA had been applied previously during the di-
agnostic workup; this meant that CBA and RIPA were per-
formed using different samples. Cohen’s kappa coefficients 
of 0.41–0.60, 0.61–0.80, and 0.81–1.00 were interpreted as 
indicating moderate, substantial, and almost perfect levels 
of agreement, respectively. All p values were two-sided, and 
a p value of <0.05 was considered statistically significant. 
Statistical analyses were performed using R software (ver-
sion 3.4.3, R Foundation for Statistical Computing, Vienna, 
Austria).
RESULTS 
Overall results of the CBA
The stable expression of MuSK mRNA and protein in the 
MuSK-HEK293 cell line was confirmed by RT-PCR and West-
ern blotting, respectively (Fig. 1). In fluorescence microsco-
py, green fluorescence was observed along the cell surface of 
the MuSK-HEK293 cells, indicating the expression of MuSK 
at the cell membranes. After adding the anti-MuSK Abs or 
sera of patients who had previously been diagnosed with 
MuSK MG, the cell membranes were stained with red fluo-
rescence that was colocalized with the green fluorescence 
(Fig. 2). No red fluorescence was detected when the same 
procedure was conducted with the sera of negative controls. 
Overall, 34 (15.6%) of the 218 samples tested for the MuSK 
Abs using the CBA displayed a positive result for MuSK Abs. 
All samples with positive MuSK Ab results were from pa-
tients diagnosed with MG. None of the 41 samples from pa-
tients with other neuromuscular diseases or the healthy con-
trols showed positive results for MuSK Abs (Supplementary 
Table 1 in the online-only Data Supplement). Representative 
images of the CBA for each level of visual scoring are shown 
in Supplementary Fig. 1 (in the online-only Data Supplement). 
Demographics and clinical features of the patients 
with MG
The present analysis was applied to 177 samples from the 
patients with MG (66 males and 111 females). The age of the 
MuSK 1
MuSK
transfected
cells
HEK293 cell
UT Vector
MuSK 2
MuSK 3
GAPDH
A  
MuSK 115 KDa
MuSK
transfected
cells
HEK293 cell
UT Vector
β-actin
B  
Fig. 1. Confirmation of the expression of MuSK mRNA and protein. 
A: Reverse-transcription polymerase chain reaction revealed the sta-
ble expression of MuSK mRNA in the MuSK-HEK293 cell line, whereas 
no bands were detected in either untransduced HEK293 cells or HEK293 
cells transduced with empty vectors. B: Western blotting also con-
firmed MuSK expression (band at 122 kDa) in the MuSK-HEK293 cell 
line. Lanes of untransduced HEK293 cells or HEK293 cells transduced 
with empty vectors showed no bands. GAPDH: glyceraldehyde 3-phos-
phate dehydrogenase, HEK293: human embryonic kidney 293, MuSK: 
muscle-specific tyrosine kinase, UT: untransduced cells, Vector: HEK293 
cells transduced with lentiviral vector that does not contain the MuSK 
gene.
A  B  C  
Fig. 2. CBA to detect anti-MuSK Abs. When HEK293 cells expressing MuSK were incubated with (A) commercially available polyclonal anti-MuSK 
Abs or (B) sera from patients with MuSK-Ab-positive MG, anti-IgG antibody binding (red fluorescence) was observed along the cell surface, indicat-
ing the binding of MuSK Abs to MuSK. This colocalized with GFP-labeled MuSK expressed on the surface of HEK293 cells (green fluorescence). In 
contrast, (C) anti-human IgG antibody binding (red fluorescence) was not observed after adding the sera from the healthy control. Scale bar: 10 
μm. CBA: cell-based assay, DAPI: 4',6-diamidino-2-phenylindole, eGFP: enhanced green fluorescent protein, HEK293: human embryonic kidney 293, 
MG: myasthenia gravis, MuSK Abs: antibodies against muscle-specific tyrosine kinase.
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patients at the time of sampling was 47.0±16.0 years. Ocular 
MG and generalized MG were present in 45 (25.4%) patients 
and 132 (74.6%) patients, respectively. Twenty-five (14.1%) 
patients had experienced a myasthenic crisis and 77 (43.5%) 
had undergone a thymectomy. 
Autoantibody profiles
The serostatus of the patients with MG based on the RIPA 
and CBA is presented in detail in Fig. 3. The serostatus of the 
samples according to the RIPA was classified as follows: 123 
AChR-Ab-positive MG, 25 AChR-Ab-negative and MuSK-
Ab-positive MG, 11 double-seronegative MG, 16 AChR-Ab-
negative MG without testing for MuSK Abs, and 2 AChR-
Ab-negative MG patients with borderline results for MuSK 
Abs. The CBA for the MuSK Abs showed a positive result in 
24 (96.0%) of 25 MuSK-Ab-positive MG patients, 8 (50.0%) 
of 16 AChR-Ab-negative MG patients with unknown MuSK 
Ab status, 1 (50%) of 2 AChR-Ab-negative MG patients with 
borderline MuSK Abs, and 1 (9.1%) of 11 double-seronega-
tive patients. The results of the CBA for the MuSK Abs were 
negative in all of the remaining patients. 
Comparison of clinical features between 
the three groups
We classified the patients with MG into three groups based 
on the presence of MuSK Abs as evaluated by CBA and of 
AChR Abs as tested using a commercial RIPA: AChR-Ab-
positive and MuSK-Ab-negative MG (AChR MG, n=123), 
AChR-Ab-negative and MuSK-Ab-positive MG (MuSK MG, 
n=34), and AChR-Ab-negative and MuSK-Ab-negative MG 
(double-seronegative MG, n=20). Detailed clinical features 
of these groups are provided in Table 1. Patients with MuSK 
MG demonstrated a marked female predominance (p< 
0.001), were more likely to show bulbofacial presentation (p= 
0.041), more frequently had MGFA Class ≥III (p<0.001), and 
were frequently treated with corticosteroids (p=0.006), cy-
closporine (p=0.005), or mycophenolate mofetil (p=0.005). 
Patients with AChR MG were more likely to have undergone 
a thymectomy (p<0.001). 
Correlation between CBA and RIPA results
We evaluated the correlation between the results of the 
RIPA and CBA. The RIPA had previously been applied at 
the time of the initial diagnosis, whereas the CBA was ap-
plied during the present study. Therefore, the RIPA and CBA 
were applied to different samples obtained in different dis-
ease states. There were 38 patients who underwent both the 
RIPA and CBA. The RIPA was performed during the active 
disease course in every case. In contrast, 4 of the 38 patients 
underwent the CBA during clinical remission, whereas the 
CBA was performed in the remaining 34 patients while they 
had MG-related symptoms. The median duration between 
the RIPA and CBA was 8.0 months (interquartile range= 
2.0–29.3 months). The RIPA results were reported as quan-
titative values in 20 of these 38 patients. The distribution of 
the MuSK Ab concentration as evaluated by the RIPA and 
the results of the CBA measured using a visual grading score 
in these patients are presented in Fig. 4A. The correlation be-
tween the RIPA and CBA results was evaluated in 36 patients 
after excluding 2 patients whose results in the RIPA were 
borderline. There was an almost perfect agreement between 
the results of the CBA measured using visual grading and the 
results of the RIPA (Cohen’s kappa=0.880, p<0.001). Only two 
samples did not show an agreement between the RIPA and 
MuSK CBA
negative
(n=123)
MuSK RIPA
negative
(n=11)
MuSK RIPA
positive
(n=25)
AChR Ab
positive
(n=123)
Patients with MG (n=177)
AChR Ab
negative
(n=54)
MuSK RIPA
borderline
(n=2)
MuSK RIPA
not done
(n=16)
MuSK CBA
negative
(n=1)
MuSK CBA
negative
(n=1)
MuSK CBA
negative
(n=8)
MuSK CBA
negative
(n=10)
MuSK CBA
positive
(n=24)
MuSK CBA
positive
(n=1)
MuSK CBA
positive
(n=1)
MuSK CBA
positive
(n=8)
Fig. 3. Serostatus of 177 patients with MG determined by MuSK RIPA and MuSK CBA. AChR Ab: acetylcholine receptor antibody, CBA: cell-based 
assay, MG: myasthenia gravis, MuSK: muscle-specific tyrosine kinase, RIPA: radioimmunoprecipitation assay.
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Table 1. Clinical characteristics of the patients with MG classified based on the results of the in-house CBA for MuSK Abs and commercially avail-
able test for AChR Abs
Clinical feature MuSK-Ab positive (n=34) AChR-Ab positive (n=123) Double seronegative (n=20) p
Age at onset, years 35.8±11.9 39.5±19.2 40.0±17.8 0.534
Sex, male 2 (3.0) 58 (47.2) 6 (30.0) <0.001*‡
Symptoms at onset
Ocular 32 (94.1) 100 (81.3) 18 (90.0) 0.171
Bulbofacial 15 (44.1) 29 (23.6) 4 (20.0) 0.041*
Limb 10 (29.4) 25 (20.3) 3 (15.0) 0.427
Neck 2 (5.9) 6 (4.9) 0 (0.0) 0.620
Respiratory 4 (11.8) 3 (2.4) 0 (0.0) 0.068
Severity <0.001*†‡
MGFA class I/II 10 (29.4) 65 (52.8) 16 (80.0)
MGFA class III/IV/V 24 (70.6) 58 (47.2) 4 (20.0)
MGFA classification “b” 32 (94.1) 45 (51.7) 7 (63.6) <0.001*‡
AChR-Ab positive, initial 0 (0.0) 121 (98.4) 0 (0.0) <0.001*
AChR-Ab titer, nmol/L - 7.7±5.6 - -
Thymectomy 3 (8.8) 71 (57.7) 3 (15.0) <0.001*†
Abnormal RNS response 28 (82.4) 92 (74.8) 10 (50.0) 0.027†‡
Treatment 
Corticosteroid 31 (91.2) 78 (63.4) 12 (60.0) 0.006*‡
Azathioprine 10 (29.4) 29 (23.6) 5 (25.0) 0.765
Cyclosporine 5 (14.7) 2 (1.6) 1 (5.0) 0.005*
Mycophenolate mofetil 5 (14.7) 2 (1.6) 1 (5.0) 0.005*
Tacrolimus 5 (14.7) 34 (27.6) 3 (15.0) 0.186
Data are mean±standard deviation or n (%) values.
*Statistically significant for AChR-Ab positive vs. MuSK-Ab positive, †Statistically significant for AChR-Ab positive vs. double seronegative, ‡Statistical-
ly significant for MuSK-Ab positive vs. double seronegative.
AChR Ab: acetylcholine receptor antibody, CBA: cell-based assay, MG: myasthenia gravis, MGFA: Myasthenia Gravis Foundation of America, MuSK Ab: 
muscle-specific tyrosine kinase antibody, RNS: repetitive nerve stimulation.
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Fig. 4. Correlations between the tests to detect MuSK Abs. A: The correlation between the CBA and the previously performed RIPA was assessed in 
20 samples from the patients with MG whose samples had previously been assessed using an RIPA, the results of which were reported as quanti-
tative values. There was an almost perfect agreement between the results of the CBA measured by visual grading and the results of the previously 
conducted RIPA (Cohen’s kappa=0.880, p<0.001). B: Correlation between the results obtained in the CBA and ELISA applied to the same samples 
was assessed in 177 samples from the patients with MG. There was also an almost perfect agreement between the results of the CBA and ELISA 
(Cohen’s kappa=0.982, p<0.001). CBA: cell-based assay, ELISA: enzyme-linked immunosorbent assay, MG: myasthenia gravis, MuSK Abs: antibodies 
against muscle-specific tyrosine kinase, RIPA: radioimmunoprecipitation assay.
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CBA: the result for MuSK Abs was positive only in the CBA 
in one patient and only in the RIPA in the other patient. 
Correlation between CBA and ELISA results
We further evaluated the correlation between the results for 
MuSK Abs obtained using the CBA and the commercially 
available ELISA. The CBA and ELISA of each patient were 
applied to the same sample. The distribution of the MuSK 
Ab concentration as evaluated by the ELISA and the results 
of CBA as measured using visual grading in 177 samples from 
the patients with MG are presented in Fig. 4B. There was an 
almost perfect agreement between the results of the CBA 
and ELISA (Cohen’s kappa=0.982, p<0.001). There was one 
sample that did not demonstrate an agreement between the 
CBA and ELISA, with the result being positive in the MuSK 
CBA but negative in the ELISA. 
DISCUSSION
We established an in-house CBA method by generating a sta-
bly transfected MuSK-HEK293 cell line. The present findings 
demonstrate excellent agreement between the results of our 
in-house CBA and two other methods: RIPA and ELISA. In 
addition, there were two cases where the serostatus was re-
vealed to be positive for MuSK Abs by the CBA, whereas MuSK 
Abs were not detected when using an RIPA or ELISA. Our 
in-house CBA can therefore be considered a reliable meth-
od for identifying the presence of MuSK Abs. 
The CBA demonstrated high sensitivity and specificity in 
detecting autoantibodies in patients with MuSK MG. Huda 
et al.18 demonstrated that the MuSK CBA is highly reliable 
for detecting MuSK Abs in patients who were previously 
known to have MuSK MG as determined by an RIPA. Fur-
thermore, the CBA detected MuSK Abs in 8% of the patients 
who were determined to be double seronegative in a RIPA. 
A previous multinational study that also used CBA detect-
ed MuSK Abs in 13% of the patients with triple-seronegative 
MG, in whom AChR Abs and MuSK Abs were not detected 
by an RIPA and antibodies against LRP4 (low-density lipo-
protein receptor-related protein 4) were not detected by CBA.11 
In particular, the CBA in that study revealed that MuSK-Ab-
positive MG is more common among patients with ocular 
MG than previously thought. In a recent study from South 
Korea, the CBA demonstrated a higher sensitivity in detect-
ing MuSK Abs than did the conventional RIPA.10 Other stud-
ies have similarly demonstrated that the seropositive rate in 
patients with MG is higher when a CBA is performed in ad-
dition to an RIPA.19,20 In the present study, none of the patients 
with other neuromuscular disorders or the healthy controls 
showed positive results for MuSK Abs in the CBA. In addi-
tion, the CBA was able to detect additional MuSK-Ab-posi-
tive cases that were previously thought to be MuSK-Ab neg-
ative or borderline based on the RIPA. These results indicate 
that the present in-house CBA is highly sensitive and specif-
ic for detecting MuSK Abs. 
In addition to its reliability and concordance with other as-
says in detecting MuSK Abs, the current CBA has strength 
in constructing a cell line stably expressing MuSK using a 
lentivirus. Although the detailed method of transfecting 
MuSK DNA was not reported for some of the previous stud-
ies, most of them used transiently transfected HEK293 cells 
in CBAs for detecting MuSK Abs.11,21,22 Transient transfec-
tion can be performed both easily and rapidly, but it has limi-
tations in the duration of protein expression being short and 
the transfection needing to be conducted repeatedly. In con-
trast, a gene of interest could be integrated into the host ge-
nome by using a lentivirus, and this method has previously 
been shown to be efficient and reliable for generating stable 
cell lines,23 as demonstrated by the use of a lentivirus to gen-
erate a cell line that stably expresses MuSK protein in the pres-
ent study. 
Clinical characteristics of patients with MG who were 
MuSK-Ab positive in the CBA but not in the RIPA have been 
described previously. Huda et al.18 reported that these pa-
tients had a lower age at onset, a lower disease severity, and 
showed more favorable responses to acetylcholinesterase in-
hibitor than did MuSK-RIPA-positive patients. Tsonis et al.11 
similarly suggested that patients positive for MuSK Abs in a 
CBA but negative in an RIPA more frequently had ocular MG 
and less frequently experienced myasthenic crisis than pre-
viously thought. These studies suggest that the CBA may be 
useful for detecting MuSK Abs in milder forms of MG. How-
ever, in the present study, the patient who was MuSK-CBA 
positive but MuSK-RIPA negative was 72 years old and had 
a maximum severity of MGFA class V, which contrasts with 
previous studies. This apparent discrepancy may be due to 
the relatively small number of patients in the current study. 
In addition, due to the high cost of the MuSK RIPA, most of 
the tests were only applied to patients with a high probabil-
ity of having MuSK MG; that is, those with severe bulbar 
symptoms and who did not respond to acetylcholinesterase 
inhibitor. This resulted in an RIPA only being applied to three 
patients with ocular MG. Further assessments of patients with 
milder disease may reveal additional MuSK-CBA-positive 
and MuSK-RIPA-negative patients. 
One patient in the present study was positive for MuSK Abs 
in a commercially available RIPA but negative in the CBA. 
However, the CBA was performed 8 years after the RIPA, 
during which time the patient remained in pharmacologi-
cal remission under treatment with azathioprine. Although 
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little is known regarding serial changes in MuSK Ab titers, 
previous studies have demonstrated the possibility of the 
negative seroconversion of MuSK Abs. Triplett et al.24 report-
ed a patient with MuSK MG whose serum MuSK Ab con-
centration indicated negative seroconversion approximately 
6 years after treatment with rituximab and azathioprine. Simi-
larly, Hain et al.25 reported a MuSK MG patient whose serum 
MuSK Ab concentration changed from highly positive to 
negative after treatment with rituximab. In both of these pre-
vious cases, the reduction of the circulating MuSK Ab con-
centration was accompanied by the improvement of clinical 
symptoms. This is consistent with another previous observa-
tion of clinical improvement being accompanied by a signif-
icant reduction or negative seroconversion of MuSK Abs in 
patients with MuSK MG treated with rituximab.26 Therefore, 
the different results between the RIPA and CBA in the pres-
ent study may have been due to the seroconversion of MuSK 
Abs rather than differences in the sensitivities of the tests. The 
result of the present ELISA that used the same sample as in 
the CBA was also negative for MuSK Abs, which may sup-
port the hypothesis that the negative result in the CBA re-
sulted from the negative seroconversion of MuSK Abs. 
The clinical characteristics of patients with MuSK MG de-
termined based on our in-house CBA correspond well to known 
clinical features of MuSK MG. The patients with MuSK MG 
showed a marked female predominance with a mean age of 
35.8 years at onset. This is in line with previous studies find-
ing that females constituted 71.9–100% of cases,1,2,10,18,27 and 
the mean age at onset ranging from 28.9 to 43.5 years.2,10,18 
A high proportion of patients demonstrating bulbar symp-
toms has also been reported previously. The proportion of 
patients demonstrating an MGFA classification of “b” was 
94.1% in the present study and 80–100% in previous stud-
ies.4,5,27,28 The proportion of patients with MuSK MG show-
ing abnormal RNS responses was 82.4% in the present study, 
which was significantly higher than the proportion of pa-
tients with double-seronegative MG. This was similarly found 
in previous studies that analyzed the clinical characteristics 
of MuSK MG.5,29
Several limitations of the present study need to be consid-
ered when interpreting its results. First, the study was conduct-
ed at a single center and was based on a relatively small num-
ber of patients. Further assessments based on larger numbers 
of patients are required to strengthen the results. Second, the 
MuSK RIPA and CBA were applied to different serum sam-
ples obtained at different time points, and so both agreements 
and disagreements between the two assays should be inter-
preted with caution. Third, a recent study recommended using 
an IgG Fc gamma-specific secondary antibody in the MuSK 
CBA to enhance its specificity.18 In that study, the MuSK CBA 
using anti-human IgG (H+L) detected IgM that bound non-
specifically to MuSK. These nonspecific IgM antibodies failed 
to inhibit AChR clusters, and are therefore regarded as lack-
ing pathogenic potential. In another study that also used sec-
ondary antibodies that react with both heavy and light chains, 
MuSK Abs were present in 12.5% of AChR-Ab-positive MG 
patients and in 1.9% of healthy subjects.11 These results may 
reflect the nonspecific binding of the secondary antibody. 
Since anti-human IgG (H+L) was also used in the present 
study, caution is needed in interpreting these results. How-
ever, the results of the current CBA demonstrated near per-
fect agreement with the RIPA, and no samples from patients 
with other neurological disorders or healthy controls showed 
positive results in MuSK CBAs. 
In conclusion, we generated stably transfected HEK293 
cell lines expressing MuSK protein, and the results of a CBA 
utilizing this cell line demonstrated excellent agreement with 
those from both the RIPA and ELISA. Moreover, the MuSK 
CBA detected two additional cases that were MuSK-Ab neg-
ative in the RIPA and ELISA. The clinical features of the pa-
tients with MuSK MG determined based on the CBA were 
consistent with the known clinical characteristics of MuSK 
MG. The present in-house CBA can be used to reliably deter-
mine the presence of MuSK Abs. 
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